PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE STRIVE TRIAL

被引：3

作者：

Goadsby, Peter J. ^{[1
]}

Reuter, Uwe ^{[2
]}

Bonner, Jo ^{[3
]}

Broessner, Gregor ^{[4
]}

Hallstrom, Yngve ^{[5
]}

Zhang, Feng ^{[6
]}

Sapra, Sandhya ^{[7
]}

Picard, Hernan ^{[8
]}

Mikol, Daniel ^{[8
]}

Lenz, Robert ^{[8
]}

机构：

[1] Kings Coll London, London, England

[2] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany

[3] Mercy Res, St Louis, MO USA

[4] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria

[5] Stockholm Neuro Ctr, Stockholm, Sweden

[6] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA

[7] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA

[8] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2017年 / 88卷 / 05期

关键词：

D O I：

10.1136/jnnp-2017-316074.62

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页数：2

共 50 条

[21] Efficacy of erenumab (AMG 334) in chronic migraine patients with prior prophylactic treatment failure: Subgroup analysis of the phase 2, randomised, double-blind, placebo-controlled study
Ashina, Messoud
Tepper, Stewart J.
Brandes, Jan Lewis
Reuter, Uwe
Boudreau, Guy P.
Dolezil, David
Cheng, Sunfa
Leonardi, Dean
Lenz, Robert A.
Klatt, Jan
Mikol, Daniel D.
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[22] A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab in Frequent Episodic Migraine Prevention: Primary Results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial
Saper, Joel
Lipton, Richard
Kudrow, David
Hirman, Joe
Dodick, David
Silberstein, Stephen
Chakhava, George
Smith, Jeff
Biondi, David
CEPHALALGIA, 2017, 37 : 337 - 337
[23] Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Goadsby, Peter J.
Paemeleire, Koen
Broessner, Gregor
Brandes, Jan
Klatt, Jan
Zhang, Feng
Picard, Hernan
Lenz, Robert
Mikol, Daniel D.
CEPHALALGIA, 2019, 39 (07) : 817 - 826
[24] Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Ashina, Messoud
Tepper, Stewart
Brandes, Jan Lewis
Reuter, Uwe
Boudreau, Guy
Dolezil, David
Cheng, Sunfa
Zhang, Feng
Lenz, Robert
Klatt, Jan
Mikol, Daniel D.
CEPHALALGIA, 2018, 38 (10) : 1611 - 1621
[25] Reducing impaired days: Results from the STRIVE trial, a phase 3, randomised, double-blind study of erenumab for episodic migraine
Hareendran, Asha
Buse, Dawn C.
Lipton, Richard B.
Bayliss, Martha S.
Mikol, Daniel D.
Revicki, Dennis A.
Zhang, Feng
Desai, Pooja
Picard, Hernan
Kawata, Ariane K.
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[26] Patient-reported outcomes in patients with chronic migraine receiving placebo or erenumab (AMG 334) in a phase 2, randomised, double-blind study
Lipton, Richard B.
Tepper, Stewart J.
Reuter, Uwe
Silberstein, Stephen
Stewart, Walter
Leonardi, Dean
Desai, Pooja
Cheng, Sunfa
Mikol, Daniel D.
Lenz, Robert A.
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[27] Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Busse, W. W.
Wenzel, S. E.
Meltzer, E. O.
Kerwin, E. M.
Liu, M. C.
Zhang, N.
Chon, Y.
Lin, J.
Lin, S.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB202 - AB202
[28] A randomised, double-blind, placebo-controlled study of erenumab safety in patients with stable angina
Depre, Christophe
Antalik, Lubomir
Starling, Amaal
Koren, Michael
Eisele, Osaro
Mikol, Daniel D.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[29] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V.
Goadsby, P. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 28 - 29
[30] A phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant for the preventive treatment of migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V
Goadsby, P. J.
HEADACHE, 2021, 61 : 98 - 99

← 1 2 3 4 5 →